FREE subscriptions for doctors and students... click here
You have 3 more open access pages.
- apixaban is an anticoagulant that affects the blood coagulation cascade
by directly inhibiting activated factor X (factor Xa), so inhibiting thrombin
formation and the development of thrombi
- apixaban has a marketing authorisation for the 'prevention of venous thromboembolic
events (VTE) in adult patients who have undergone elective hip or knee replacement
- according to the summary of product characteristics, 11% of patients treated
with apixaban 2.5 mg twice daily in clinical trials experienced adverse reactions.
As with other anticoagulants, bleeding may occur during apixaban therapy in
patients with risk factors such as lesions liable to bleed. Common adverse
reactions are anaemia, haemorrhage, contusion and nausea. For full details
of side effects and contraindications, see the summary of product characteristics
NICE have stated that "..Apixaban is recommended as an option for the
prevention of venous thromboembolism in adults after elective hip or knee replacement
Last reviewed 04/2019